$90.07
0.23% day before yesterday
Nasdaq, Nov 26, 11:05 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$90.07
+14.82 19.69% 1M
+44.41 97.26% 6M
+51.47 133.34% YTD
+45.24 100.91% 1Y
+82.71 1,123.78% 3Y
+66.94 289.41% 5Y
+78.37 669.83% 10Y
+78.37 669.83% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.21 0.23%

Key metrics

Basic
Market capitalization
$5.6b
Enterprise Value
$5.1b
Net debt
positive
Cash
$576.1m
Shares outstanding
62.5m
Valuation (TTM | estimate)
P/E
126.9 | negative
P/S
26.9 | 86.7
EV/Sales
24.2 | 77.9
EV/FCF
79.3
P/B
8.7
Financial Health
Equity Ratio
90.7%
Return on Equity
40.8%
ROCE
2.9%
ROIC
17.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$209.2m | $64.9m
EBITDA
$20.5m | $-153.7m
EBIT
$19.0m | $-154.0m
Net Income
$45.9m | $-126.2m
Free Cash Flow
$63.7m
Growth (TTM | estimate)
Revenue
-35.4% | -85.1%
EBITDA
-86.5% | -160.1%
EBIT
-87.3% | -160.9%
Net Income
-73.1% | -145.9%
Free Cash Flow
-72.2%
Margin (TTM | estimate)
Gross
-
EBITDA
9.8% | -236.8%
EBIT
9.1%
Net
21.9% | -194.4%
Free Cash Flow
30.5%
More
EPS
$0.7
FCF per Share
$1.0
Short interest
10.7%
Employees
126
Rev per Employee
$3.5m
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
209 209
35% 35%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 42 42
0% 0%
20%
- Research and Development Expense 148 148
12% 12%
71%
20 20
87% 87%
10%
- Depreciation and Amortization 1.44 1.44
45% 45%
1%
EBIT (Operating Income) EBIT 19 19
87% 87%
9%
Net Profit 46 46
73% 73%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Accesswire
22 days ago
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study ...
Neutral
Accesswire
25 days ago
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025. ASH Pr...
Positive
Seeking Alpha
about 2 months ago
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its oral immunology drug icotrokinra and blockbuster potential of rusfertide for polycythemia vera, both with strong partnership structures. A JNJ acquisition could save milestone payments, secure future...
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today